DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Patent/Miscellaneous
Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China
- Aladdin has developed patented AI-platform together with its partner IIAT in China
- The innovative AI-driven platform marks a turning point in the early diagnostics of heart diseases
- Next step is gaining patent approval also in the USA and Europe
BERLIN/LONDON February 24, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has developed together with its partner IIAT (Imperial Institute of Advanced Technology) an innovative AI-powered data analysis platform for cardiovascular diseases. The platform has just successfully gained three patents in China.
Aladdin achieves a milestone in the early diagnostics of cardiovascular diseases. By combining multimodal data specifically integrated AI-driven blood analysis, the Company brings a novel approach of early diagnostics to market. Moreover, most other currently available AI approaches reflect the reliance of the industry on utilising cardiac images as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple complexities that involve the disease and its underlying pathways.
The AI-data platform has gained three patents in China that include:
The IIAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies as well as projects in the field of healthcare from Europe to China and promoting them in China.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "The achievement of three patents in China is a further acknowledgment of our ability in improving the world of healthcare diagnostics with our expertise and together with our important network of international partners." Under the agreement with IIAT, Aladdin has all international rights to license the AI-technology in Europe, UK and the USA, but not in China. The Company is planning to seek patent approval in the USA and Europe as next step.
As part of the new international growth strategy, Aladdin will list its shares on the OTC market in the USA.
For further information:
Aladdin Healthcare Technologies Ltd.
24.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
Aladdin Healthcare Technologies SE
Unter den Linden 10
Regulated Market in Dusseldorf
EQS News ID:
End of News
DGAP News Service